<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03283228</url>
  </required_header>
  <id_info>
    <org_study_id>Myeloid Leukemia Markers</org_study_id>
    <nct_id>NCT03283228</nct_id>
  </id_info>
  <brief_title>Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia</brief_title>
  <official_title>Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.

        2. Study correlation between CD56 and CD11b expression with haematological parameters in
           cases of adult AML.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could
           predict a poor prognosis for AML patients.

        2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely
           related to the prognosis of AML patients
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CD11b and CD56 marker</measure>
    <time_frame>24 month</time_frame>
    <description>Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>CD11b and CD56 markers</arm_group_label>
    <description>Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haematological parameters in cases of adult AML</arm_group_label>
    <description>Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cd11b and Cd56 markers</intervention_name>
    <description>The expression of CD11b and CD56 in newly diadnosed cases of AML</description>
    <arm_group_label>CD11b and CD56 markers</arm_group_label>
    <arm_group_label>Haematological parameters in cases of adult AML</arm_group_label>
    <other_name>Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Anew diagnosis cases of adult AML
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Anew diagnosis cases of adult AML

        Exclusion Criteria:

          1. Pediatric AML .

          2. follow up cases of adult AML
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shaaban Helal, PHD</last_name>
    <phone>01005688567</phone>
    <email>Elhelal2007@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eman Salah Eldin, lecture</last_name>
    <phone>01028030966</phone>
    <email>Emansalah.eldin@yahoo.com</email>
  </overall_contact_backup>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2017</study_first_submitted>
  <study_first_submitted_qc>September 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Z A Kamel</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

